Description: IMIDomics is an emerging global enterprise which combines exclusive access to data with biological insights that will lead to the discovery, targeting, and development of medicines for immune-mediated inflammatory diseases.
Proprietary real-world data, clinical data, multi-omics biomolecular data, and access to samples from patients
Multi‑dimensional, integrated machine learning target discovery platform
Currently yielding novel, disease‑relevant, druggable targets